Compare VCEL & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | ENOV |
|---|---|---|
| Founded | 1989 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1996 | 2008 |
| Metric | VCEL | ENOV |
|---|---|---|
| Price | $33.54 | $24.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $58.50 | $48.75 |
| AVG Volume (30 Days) | 423.1K | ★ 1.1M |
| Earning Date | 05-18-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.09 | $6.49 |
| Revenue Next Year | $17.96 | $5.56 |
| P/E Ratio | $105.00 | ★ N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $29.24 | $21.00 |
| 52 Week High | $49.10 | $40.70 |
| Indicator | VCEL | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 51.45 |
| Support Level | $29.59 | $21.30 |
| Resistance Level | $38.48 | $26.41 |
| Average True Range (ATR) | 1.47 | 1.21 |
| MACD | -0.36 | 0.23 |
| Stochastic Oscillator | 9.47 | 52.80 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.